
|Videos|August 3, 2015
Will Biosimilars Impact the Cost of Specialty Drugs?
Author(s)Davy James, Managing Editor
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Advertisement
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Long COVID and Brain Health
2
Rocatinlimab Demonstrates Significant Efficacy and Safety in Phase 3 Trials for Moderate-to-Severe Atopic Dermatitis
3
Emerging Therapeutic Strategies Transforming Myelofibrosis Care in 2026
4
Depression May Be an Early Manifestation of Neurodegenerative Changes Leading to Movement Disorders
5
















